Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Non-Current Assets (2016 - 2025)

Avalo Therapeutics' Non-Current Assets history spans 12 years, with the latest figure at $11.2 million for Q4 2025.

  • For Q4 2025, Non-Current Assets fell 5.66% year-over-year to $11.2 million; the TTM value through Dec 2025 reached $45.4 million, down 7.48%, while the annual FY2025 figure was $11.2 million, 5.66% down from the prior year.
  • Non-Current Assets reached $11.2 million in Q4 2025 per AVTX's latest filing, down from $11.3 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $18.4 million in Q4 2021 to a low of $11.2 million in Q4 2025.
  • Average Non-Current Assets over 5 years is $14.9 million, with a median of $16.7 million recorded in 2023.
  • Peak YoY movement for Non-Current Assets: increased 5.75% in 2022, then fell 26.3% in 2024.
  • A 5-year view of Non-Current Assets shows it stood at $18.4 million in 2021, then dropped by 7.72% to $17.0 million in 2022, then dropped by 25.68% to $12.6 million in 2023, then decreased by 6.0% to $11.8 million in 2024, then decreased by 5.66% to $11.2 million in 2025.
  • Per Business Quant, the three most recent readings for AVTX's Non-Current Assets are $11.2 million (Q4 2025), $11.3 million (Q3 2025), and $11.4 million (Q2 2025).